Technical Perspectives on Biotech Stocks -- Alder Biopharma, Alexion Pharma, Alnylam Pharma, and Amgen

Thursday, March 8, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 8, 2018 /PRNewswire/ strives to bring the best free research to the investment community. 

Today we are offering reports on ALDR, ALXN, ALNY, and AMGN which can be accessed for free by signing up to Forbes reported on March 05th, 2018, that in the prior week,
Biotechnology firms raised $758 million from venture capitalists (VCs) and angel investors, according to an analysis by Pitchbook, a data provider that tracks venture and private equity investments. In the year-to-date, VCs have poured $2.8 billion into biotechnology startups. That means that in the first two months of 2018, VCs have invested more in biotechnology firms than they did in all of any year before 2014, the report further noted. Today, scans Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Amgen Inc. (NASDAQ: AMGN). All you have to do is sign up today for this free limited time offer by clicking the link below.

Alder Biopharmaceuticals

Shares in Washington headquartered Alder Biopharmaceuticals Inc. ended Wednesday's trading session flat at $14.90. The stock recorded a trading volume of 1.56 million shares. The Company's shares have gained 12.88% in the last month and 36.70% over the last three months. The stock is trading 18.46% above its 200-day moving average. Moreover, shares of Alder Biopharma have a Relative Strength Index (RSI) of 57.92.

On March 05th, 2018, Alder Biopharma announced that Mark J. Litton, Ph.D., MBA, Chief Business Officer, will provide a business overview and update at the 38th Annual Cowen & Co. Health Care Conference on March 12th, 2018, at 4:50 p.m. ET in Boston, Massachusetts. The live audio webcast of the event can be accessed on the Events & Presentations page under the Investors section of the Company's website. Get the full research report on ALDR for free by clicking below at:

Alexion Pharmaceuticals

Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock rose slightly by 0.21%, closing the day at $118.38 with a total trading volume of 1.47 million shares. The Company's shares have advanced 5.02% in the past month. The stock is trading 1.21% below its 50-day moving average. Additionally, shares of Alexion Pharma have an RSI of 49.79. 

On February 27th, 2018, Alexion Pharma (ALXN) and the Manton Center for Orphan Disease Research at Boston Children's Hospital announced a collaboration to enable rapid and precise diagnoses for patients with suspected rare diseases by combining the latter's expertise in decoding and treating rare diseases with ALXN's genomics and data sciences capabilities. Access the free research report on ALXN now by signing up at:

Alnylam Pharmaceuticals

On Wednesday, shares in Massachusetts headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 788,142 shares. The stock ended the day 0.60% higher at $123.99. The Company's shares have advanced 148.28% over the past year. The stock is trading above its 200-day moving average by 17.73%. Furthermore, shares of Alnylam Pharma have an RSI of 52.03.  

On February 16th, 2018, research firm B. Riley FBR, Inc. reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $205 a share to $200 a share.

On March 06th, 2018, Alnylam Pharma announced that its management will present Company overviews at the Cowen and Company 38th Annual Healthcare Conference on March 13th, 2018, at 12:00 p.m. ET at the Boston Marriott Copley Place in Boston. Management will also present at the Barclays Global Healthcare Conference on Thursday, March 15th, 2018, at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, Florida. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ALNY at:


Thousand Oaks, California headquartered Amgen Inc.'s stock dropped 1.48%, finishing yesterday's session at $187.53. A total volume of 6.48 million shares was traded, which was above their three months average volume of 4.48 million shares. The Company's shares have advanced 7.31% in the last month and 5.72% over the past year. The stock is trading above its 200-day moving average by 6.21%. Additionally, shares of Amgen have an RSI of 56.32.  

On February 12th, 2018, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $192 a share to $200 a share.

On February 27th, 2018, Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion, recommending a label variation for Neulasta® (pegfilgrastim) to include the Neulasta® Onpro® Kit. Neulasta® is indicated in the European Union for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy, with the exception of chronic myeloid leukemia and myelodysplastic syndromes. Aspiring Member, please take a moment to register below for your free research report on AMGN at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store